Edition:
United States

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

276.50DKK
3:03am EST
Change (% chg)

kr.1.00 (+0.36%)
Prev Close
kr.275.50
Open
kr.276.00
Day's High
kr.276.50
Day's Low
kr.276.00
Volume
2,378
Avg. Vol
152,504
52-wk High
kr.306.00
52-wk Low
kr.197.00

BAVA.CO

Chart for BAVA.CO

About

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate... (more)

Overall

Beta: 1.14
Market Cap(Mil.): kr.8,590.95
Shares Outstanding(Mil.): 31.35
Dividend: --
Yield (%): --

Financials

  BAVA.CO Industry Sector
P/E (TTM): -- 29.93 30.76
EPS (TTM): -2.23 -- --
ROI: -3.27 15.46 14.89
ROE: -3.38 16.64 16.30

BRIEF-Bavarian Nordic Q3 EBIT swings to profit of DKK 124.8 million

* Q3 revenue 452.3 million Danish crowns ($68.1 million) versus 79.1 million crowns year ago

Nov 09 2016

BRIEF-Bavarian Nordic starts Phase 2 clinical trial of RSV vaccine

* Top-line results from study are anticipated around mid-2017

Oct 18 2016

BRIEF-Bavarian Nordic starts Phase 2 combination trial of PROSTVAC and Ipilimumab

* Announces initiation of Phase 2 combination trial of PROSTVAC and Ipilimumab in patients with localized prostate cancer

Oct 10 2016

BRIEF-Bavarian Nordic names Christopher Heery Chief Medical Officer

* Most recently, Dr. Heery was Director of Clinical Trials Group of Laboratory of Tumor Immunology and Biology at National Cancer Institute Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Sep 28 2016

BRIEF-Bavarian Nordic: Janssen completes submission for EUAL for Ebola vaccine regimen to WHO

* Said on Monday its partner, Janssen had completed submission for Emergency Use Assessment and Listing (EUAL) for its Ebola vaccine regimen to World Health Organization

Sep 13 2016

BRIEF-Bavarian Nordic Q2 EBIT swings to loss DKK 54.0 million

* H1 revenue 139 million Danish crowns ($21 million) versus 624 million crowns year ago

Aug 17 2016

BRIEF-Bavarian Nordic starts Phase 1 trial of MVA-BN-based Yellow Fever Vaccine

* Announced initiation of a Phase 1 clinical trial of MVA-BN-based Yellow Fever Vaccine

Jul 27 2016

Earnings vs. Estimates